Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-FR Version v4-FR
Language French French
Date Updated 2020-12-17 2020-10-15
Drug Identification Number 02436256 02436256
Brand name ACT LATANOPROST/TIMOLOL ACT LATANOPROST/TIMOLOL
Common or Proper name LATANOPROST-TIMOLOL 0.005% LATANOPROST-TIMOLOL 0.005%
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients LATANOPROST TIMOLOL LATANOPROST TIMOLOL
Strength(s) 50MCG 5MG 50MCG 5MG
Dosage form(s) SOLUTION SOLUTION
Route of administration OPHTHALMIC OPHTHALMIC OPHTHALMIC OPHTHALMIC
Packaging size 2.5ML 2.5ML
ATC code S01ED S01ED
ATC description ANTIGLAUCOMA PREPARATIONS AND MIOTICS ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2020-09-10 2020-09-10
Estimated end date 2020-12-31 2020-11-30
Actual end date 2020-12-16
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments